MoonLake Immunotherapeutics (NASDAQ: MLTX) started the day on Wednesday, with a price increase of 4.54% at $10.59, before settling in for the price of $10.13 at the close. Taking a more long-term approach, MLTX posted a 52-week range of $5.95-$62.75.
The Healthcare sector firm’s twelve-monthly sales growth has been -319.65% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -319.65%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -83.62%. This publicly-traded company’s shares outstanding now amounts to $63.47 million, simultaneously with a float of $55.13 million. The organization now has a market capitalization sitting at $680.21 million. At the time of writing, stock’s 50-day Moving Average stood at $29.75, while the 200-day Moving Average is $40.61.
MoonLake Immunotherapeutics (MLTX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. MoonLake Immunotherapeutics’s current insider ownership accounts for 13.18%, in contrast to 79.08% institutional ownership. According to the most recent insider trade that took place on Oct 08 ’25, this organization’s Chief Financial Officer bought 10,870 shares at the rate of 9.09, making the entire transaction reach 98,808 in total value, affecting insider ownership by 627,536. Preceding that transaction, on Sep 29 ’25, Company’s Former 10% Owner sold 6,494,151 for 7.21, making the whole transaction’s value amount to 46,827,628. This particular insider is now the holder of 2,000,000 in total.
MoonLake Immunotherapeutics (MLTX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.86 per share during the current fiscal year.
MoonLake Immunotherapeutics’s EPS decrease for this current 12-month fiscal period is -83.62% and is forecasted to reach -3.68 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -21.21% through the next 5 years, which can be compared against the -319.65% growth it accomplished over the previous five years trading on the market.
MoonLake Immunotherapeutics (NASDAQ: MLTX) Trading Performance Indicators
Let’s observe the current performance indicators for MoonLake Immunotherapeutics (MLTX). It’s Quick Ratio in the last reported quarter now stands at 16.65.
In the same vein, MLTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.79, a figure that is expected to reach -0.95 in the next quarter, and analysts are predicting that it will be -3.68 at the market close of one year from today.
Technical Analysis of MoonLake Immunotherapeutics (MLTX)
If we take a close look at the recent performances of MoonLake Immunotherapeutics (NASDAQ: MLTX), its last 5-days Average volume was 3.04 million that shows progress from its year to date volume of 1.71 million. During the previous 9 days, stock’s Stochastic %D was recorded 76.95% While, its Average True Range was 40.44.
Raw Stochastic average of MoonLake Immunotherapeutics (MLTX) in the period of the previous 100 days is set at 8.17%, which indicates a major fall in contrast to 91.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.52 that was lower than 1.86 volatility it exhibited in the past 100-days period.
